deferiprone has been researched along with pargyline in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, R; Chen, Y; Gu, J; Han, J; Su, J; Xie, Y; Yang, K; Yu, S; Yuan, S; Zhang, C; Zhou, T | 1 |
| Bai, R; Gu, J; Guo, J; Jiang, X; Lv, Y; Mi, Z; Shi, Y; Xie, Y; Yao, C; Zhang, C; Zhou, T | 1 |
2 other study(ies) available for deferiprone and pargyline
| Article | Year |
|---|---|
Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cell Line, Tumor; Cell Survival; Coumarins; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrogen Peroxide; Iron Chelating Agents; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pyridines; Scopolamine; Structure-Activity Relationship | 2019 |
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Behavior, Animal; Binding Sites; Cell Survival; Coumarins; Disease Models, Animal; Drug Design; Humans; Iron Chelating Agents; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Monoamine Oxidase; Monoamine Oxidase Inhibitors; PC12 Cells; Peptide Fragments; Rats; Structure-Activity Relationship | 2020 |